Gilead Sciences (GILD) PT Lowered to $77 at RBC Capital Following Mixed TROPiCS-02 Data, Sees Debate Shifting to Value vs. Capital Use
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) to $77.00 (from $85.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
